Xu Y, Wang XS, Chen Y, et al. - Researchers performed a randomized controlled phase 2 trial determining the efficacy of Renshen Yangrong Tang (RSYRT) for reducing cancer-related fatigue. They analyzed 83 cancer survivors with moderate or severe fatigue (rated ≥ 4 on a 0–10 scale) who were randomized to receive either herbal extract granules of RSYRT or a low dose of a single herb (huangqi) twice a day for 6 weeks (control group, 42; intervention group, 41). Outcomes support the efficacy of RSYRT therapy in providing statistical and clinical improvement in fatigue severity and functioning when compared with control therapy. These findings justify investigating RSYRT’s effectiveness in the real world.